Rapid high-performance liquid chromatographic determination of docetaxel (Taxotere) in plasma using liquid-liquid extraction

被引:45
作者
Ciccolini, J
Catalin, J
Blachon, MF
Durand, A
机构
[1] Fac Pharm Marseille, Lab Toxicocinet & Pharmacocinet, F-13385 Marseille 5, France
[2] CHU Timone, Federat Pharmacol Med & Clin & Pharmacocinet, F-13005 Marseille, France
来源
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES | 2001年 / 759卷 / 02期
关键词
docetaxel; Taxotere;
D O I
10.1016/S0378-4347(01)00238-9
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
A new rapid and sensitive high-performance liquid chromatographic method for analysis of docetaxel (Taxotere) in human plasma was developed and validated. After adding an internal standard (paclitaxel, Taxol), plasma was extracted following a simple liquid-liquid extraction with diethyl ether. Extraction efficiency averaged 95% for docetaxel. Separation was performed using a Nudeosil (C18) 5 mum column, monitored at 227 nm, The isocratic mobile phase consisted of acetonitrile-acetate buffer, pH 5-tetrahydrofuran (45:50:5, v/v) pumped at a flow-rate of 1.8 ml/min. The limit of quantification for docetaxel in plasma was 12.5 ng/ml. Retention times for docetaxel and paclitaxel were 7.7 and 9 min, respectively. Standard curves were linear over a range of 25-1000 ng/ml. This new method is rapid since it does not require time-consuming extraction procedures, or complex chromatographic conditions. This rapidity, along with the lack of chromatographic interferences with various other drugs likely to be administered to the cancer patients (pain killers, corticoids, antiemetics drugs) make this method suitable for daily routine analysis of Taxotere, a major anticancer drug extensively used in clinical oncology. (C) 2001 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:299 / 306
页数:8
相关论文
共 17 条
[1]  
Ardiet CJ, 1999, INVEST NEW DRUG, V17, P325
[2]  
BISSETT D, 1993, CANCER RES, V53, P523
[3]   PHASE-I CLINICAL-TRIAL OF TAXOTERE ADMINISTERED AS EITHER A 2-HOUR OR 6-HOUR INTRAVENOUS-INFUSION [J].
BURRIS, H ;
IRVIN, R ;
KUHN, J ;
KALTER, S ;
SMITH, L ;
SHAFFER, D ;
FIELDS, S ;
WEISS, G ;
ECKARDT, J ;
RODRIGUEZ, G ;
RINALDI, D ;
WALL, J ;
COOK, G ;
SMITH, S ;
VREELAND, F ;
BAYSSAS, M ;
LEBAIL, N ;
VONHOFF, D .
JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (05) :950-958
[4]   Docetaxel in combination with epirubicin in metastatic breast cancer: pharmacokinetic interactions [J].
Ceruti, M ;
Tagini, V ;
Recalenda, V ;
Arpicco, S ;
Cattel, L ;
Airoldi, M ;
Bumma, C .
FARMACO, 1999, 54 (11-12) :733-739
[5]   Clinical pharmacokinetics of docetaxel [J].
Clarke, SJ ;
Rivory, LP .
CLINICAL PHARMACOKINETICS, 1999, 36 (02) :99-114
[6]   The taxoids - Comparative clinical pharmacology and therapeutic potential [J].
Eisenhauer, EA ;
Vermorken, JB .
DRUGS, 1998, 55 (01) :5-30
[7]  
Gaillard-France S, 1999, THERAPIE, V54, P315
[8]   THE TAXOIDS - PACLITAXEL AND DOCETAXEL [J].
GELMON, K .
LANCET, 1994, 344 (8932) :1267-1272
[9]   Quantification of paclitaxel metabolites in human plasma by high-performance liquid chromatography [J].
Huizing, MT ;
Sparreboom, A ;
Rosing, H ;
vanTellingen, O ;
Pinedo, HM ;
Beijnen, JH .
JOURNAL OF CHROMATOGRAPHY B-BIOMEDICAL APPLICATIONS, 1995, 674 (02) :261-268
[10]   Sensitive determination of docetaxel in human plasma by liquid-liquid extraction and reversed-phase high-performance liquid chromatography [J].
Loos, WJ ;
Verweij, J ;
Nooter, K ;
Stoter, G ;
Sparreboom, A .
JOURNAL OF CHROMATOGRAPHY B, 1997, 693 (02) :437-441